US Drug Recall Register

FDA Drug Recalls

2,661 recalls, newest first

Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.

Breckenridge Pharmaceutical, Inc. NDC 51991-747-10 D-0308-2025
Class II · Moderate risk Ongoing

Clindamycin HCl

Reason CGMP Deviations

RemedyRepack Inc. D-0378-2025
Class II · Moderate risk Ongoing

Haloperidol Decanoate Injection

Reason Lack of Assurance of Sterility: Media fill with bacterial contamination

Somerset Therapeutics Private Limited NDC 70069-383-10 D-0358-2025
Class II · Moderate risk Ongoing

Haloperidol Decanoate Injection 100mg/mL

Reason Lack of Assurance of Sterility: Media fill with bacterial contamination

Somerset Therapeutics Private Limited NDC 68001-581-41 D-0357-2025
Class II · Moderate risk Ongoing

Haloperidol Decanoate Injection 50mg/mL

Reason Lack of Assurance of Sterility: Media fill with bacterial contamination

Somerset Therapeutics Private Limited NDC 68001-580-41 D-0356-2025
Class II · Moderate risk Ongoing

Haloperidol Decanoate Injection 50mg/mL

Reason Lack of Assurance of Sterility: Media fill with bacterial contamination

Somerset Therapeutics Private Limited NDC 70069-381-01 D-0355-2025
Class II · Moderate risk Ongoing

Methocarbamol Injection USP 1

Reason Lack of Assurance of Sterility: Media fill with bacterial contamination

Somerset Therapeutics Private Limited NDC 70069-101-25 D-0354-2025
Class II · Moderate risk Ongoing

Atorvastatin Calcium Tablets USP 40 mg

Reason Failed dissolution specifications: lower than specifications

Biocon Pharma INC NDC 70377-079-13 D-0306-2025
Class I · High risk Ongoing

Levetiracetam 0.75% in Sodium Chloride Injection 1

Reason LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.

Dr. Reddy's Laboratories, Inc. NDC 43598-636-52 D-0365-2025
Class II · Moderate risk Ongoing

Pravastatin Sodium Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 16714-570-02 D-0350-2025
Class II · Moderate risk Ongoing

Pravastatin Sodium Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 16714-559-01 D-0349-2025
Class II · Moderate risk Ongoing

Cetirizine Hydrochloride Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 72657-129-35 D-0348-2025
Class II · Moderate risk Ongoing

Acetaminophen and Ibuprofen

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 72657-157-74 D-0347-2025
Class II · Moderate risk Ongoing

Naproxen Sodium Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-179-01 D-0346-2025
Class II · Moderate risk Ongoing

Saxagliptin Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-726-30 D-0345-2025
Class II · Moderate risk Ongoing

Clindamycin Hydrochloride Capsules

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-144-01 D-0344-2025
Class II · Moderate risk Ongoing

Lacosamide Tablets 150mg

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-680-60 D-0343-2025
Class II · Moderate risk Ongoing

Pravastatin Sodium Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-196-05 D-0341-2025
Class II · Moderate risk Ongoing

Rosuvastatin Tablets 40mg

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-264-30 D-0339-2025
Class II · Moderate risk Ongoing

Prochlorperazine Maleate Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-890-01 D-0338-2025
Class II · Moderate risk Ongoing

Lacosamide Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-678-60 D-0337-2025